Legend Historical Balance Sheet
LEGN Stock | USD 43.28 1.94 4.69% |
Trend analysis of Legend Biotech Corp balance sheet accounts such as Total Stockholder Equity of 1.3 B provides information on Legend Biotech's total assets, liabilities, and equity, which is the actual value of Legend Biotech Corp to its prevalent stockholders. By breaking down trends over time using Legend Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Legend Biotech Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Legend Biotech Corp is a good buy for the upcoming year.
Legend Biotech Inventory |
|
Legend |
About Legend Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Legend Biotech Corp at a specified time, usually calculated after every quarter, six months, or one year. Legend Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Legend Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Legend currently owns. An asset can also be divided into two categories, current and non-current.
Legend Biotech Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Legend Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Legend Biotech Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Legend Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Legend Biotech Corp are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most accounts from Legend Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Legend Biotech Corp current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. At this time, Legend Biotech's Inventory is very stable compared to the past year. As of the 5th of June 2024, Other Stockholder Equity is likely to grow to about 2.8 B, while Total Assets are likely to drop about 938.8 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 211.4M | 260.9M | 140.1M | 147.9M | Total Assets | 1.1B | 1.3B | 1.8B | 938.8M |
Legend Biotech balance sheet Correlations
Click cells to compare fundamentals
Legend Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Legend Biotech balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 287.7M | 721.0M | 1.1B | 1.3B | 1.8B | 938.8M | |
Other Current Liab | 70.9M | 99.2M | 211.4M | 260.9M | 140.1M | 147.9M | |
Total Current Liabilities | 127.8M | 161.2M | 280.3M | 297.8M | 216.4M | 203.5M | |
Total Stockholder Equity | (122.9M) | 280.3M | 471.2M | 744.3M | 1.3B | 1.3B | |
Other Liab | 277.8M | 277.7M | 244.8M | 7.9M | 7.1M | 6.7M | |
Net Tangible Assets | (123.4M) | 277.4M | 466.5M | 740.9M | 852.0M | 894.6M | |
Retained Earnings | (127.3M) | (430.8M) | (817.0M) | (966.5M) | (1.5B) | (1.4B) | |
Accounts Payable | 9.6M | 5.2M | 7.0M | 32.9M | 20.2M | 13.6M | |
Cash | 83.4M | 455.7M | 688.9M | 786.0M | 1.3B | 1.3B | |
Other Assets | 665K | 4.2M | 7.3M | 67.7M | 1.0 | 0.95 | |
Cash And Short Term Investments | 158.9M | 505.7M | 882.4M | 1.0B | 1.3B | 1.4B | |
Net Receivables | 35.8M | 85.0M | 63.2M | 90K | 157.1M | 164.9M | |
Inventory | 1.2M | 1.8M | 1.7M | 10.4M | 19.4M | 20.4M | |
Other Stockholder Equity | 3.9M | 430.8M | 817.0M | 744.3M | 2.6B | 2.8B | |
Total Liab | 410.6M | 440.8M | 647.2M | 586.7M | 589.9M | 522.0M | |
Total Current Assets | 207.1M | 592.9M | 948.8M | 1.1B | 1.5B | 770.5M | |
Intangible Assets | 5.1M | 7.7M | 4.7M | 3.4M | 155.3M | 163.0M | |
Property Plant Equipment | 79.4M | 121.1M | 152.9M | 160.8M | 184.9M | 100.7M | |
Short Long Term Debt Total | 6.1M | 3.4M | 123.0M | 284.5M | 328.7M | 345.1M | |
Property Plant And Equipment Net | 75.5M | 121.3M | 155.1M | 161.7M | 189.7M | 135.0M | |
Current Deferred Revenue | 46.3M | 55.3M | 60.9M | 451K | 53.0M | 34.2M | |
Net Debt | (77.3M) | (452.3M) | (566.0M) | (501.5M) | (949.4M) | (901.9M) | |
Non Current Assets Total | 80.6M | 128.1M | 169.6M | 231.8M | 350.8M | 194.9M | |
Non Currrent Assets Other | 665K | 4.0M | 5.1M | 66.8M | 152.4M | 160.0M | |
Common Stock Shares Outstanding | 132.0M | 118.2M | 140.9M | 159.0M | 176.1M | 151.5M | |
Short Term Investments | 75.6M | 50M | 193.5M | 239.6M | 31.0M | 29.5M | |
Liabilities And Stockholders Equity | 287.7M | 721.0M | 1.1B | 1.3B | 1.8B | 1.1B | |
Non Current Liabilities Total | 282.8M | 279.6M | 366.9M | 288.9M | 373.5M | 339.7M | |
Capital Lease Obligations | 6.1M | 3.4M | 2.5M | 23.6M | 47.3M | 49.7M | |
Other Current Assets | 11.3M | 580.7M | 1.4M | 1.1B | 12.2M | 11.6M | |
Net Invested Capital | (122.9M) | 280.3M | 591.7M | 1.0B | 1.5B | 1.6B | |
Property Plant And Equipment Gross | 74.8M | 116.5M | 155.1M | 161.7M | 224.7M | 140.2M | |
Accumulated Other Comprehensive Income | (122.9M) | 280.2M | 471.2M | 744.3M | 98.9M | 94.0M | |
Net Working Capital | 79.3M | 431.7M | 668.5M | 801.3M | 1.3B | 1.3B | |
Short Term Debt | 1.0M | 1.5M | 911K | 3.6M | 3.2M | 1.9M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Legend Stock
When determining whether Legend Biotech Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotech Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotech Corp Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.58) | Revenue Per Share 1.902 | Quarterly Revenue Growth 1.587 | Return On Assets (0.18) | Return On Equity (0.51) |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.